Topotecan

Evidence Level: L5

Predicted Indications: 2

Topotecan

Pharmacist Assessment Report

Topotecan: From Ovarian Cancer to Female Breast Carcinoma

One-Sentence Summary

Topotecan is a chemotherapy drug originally used to treat ovarian cancer. The TxGNN model predicts it may be effective for female breast carcinoma, with 3 registered clinical trials and 20 publications currently supporting this direction. Most of these are early-phase, terminated or indirect, so the evidence is limited.

Quick Overview

Item	Content
Original Indication	Ovarian cancer (including several ovarian subtypes such as germ cell tumour and yolk sac tumour)
Predicted New Indication	Female breast carcinoma
TxGNN Prediction Score	0.9992
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 4 of 4)
Number of DINs	4 (marketed: 4)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, topotecan is a topoisomerase I inhibitor. It causes DNA damage in rapidly dividing cells, and its efficacy in ovarian cancer has been established.

Preclinical work suggests that topoisomerase I inhibition can produce synthetic lethality in MYC-driven cancers through abnormal accumulation of R-loops. This is relevant to MYC-amplified breast cancer subtypes such as triple-negative disease. Topotecan is also a substrate of the BCRP/ABCG2 efflux transporter, which is expressed in breast cancer and may drive drug resistance.

The very high TxGNN score supports biological plausibility, but it is a model prediction and not clinical evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00006032	Phase 2	Terminated	Not reported	Intensive-dose topotecan, ifosfamide/mesna and etoposide followed by autologous stem cell rescue in metastatic breast cancer; the multi-agent, high-dose regimen means topotecan’s own contribution cannot be isolated
NCT02419495	Phase 1	Terminated	221	Safety of selinexor combined with several standard chemotherapies in advanced solid tumours; no breast-specific topotecan signal
NCT06840886	Phase 1	Recruiting	426	First-in-human dose escalation and expansion study of PHST001 in advanced solid tumours; topotecan’s role is unclear and no efficacy results exist

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9413954	1997	Phase 2 trial	Br J Cancer	Continuous infusional topotecan in advanced breast cancer and NSCLC showed no evidence of increased efficacy
11455218	2001	Pilot study	Onkologie	Topotecan as primary chemotherapy for brain metastases in metastatic breast cancer
9425961	1997	Review	Semin Oncol	Potential role of topotecan in advanced breast cancer
9445630	1997	Review	Gynakol Geburtshilfliche Rundsch	New drugs in breast carcinoma therapy: status and outlook
7910993	1994	Review	World J Surg	Overview of metastatic breast cancer management
25236865	2015	Review	AAPS J	BCRP/ABCG2 drug transport; topotecan is a substrate, relevant to resistance
37987734	2023	Preclinical	Cancer Res	TOP1 inhibition causes synthetic lethality in MYC-driven breast cancer cells via R-loop accumulation
10930538	2000	Preclinical	Biochem Pharmacol	BCRP expression in topotecan-resistant breast carcinoma cells
10472342	1999	Preclinical	Anticancer Res	Xenograft sensitivity to doxorubicin, cisplatin, irinotecan and topotecan, including breast lines
39657238	2024	Preclinical	ACS Appl Mater Interfaces	Topotecan-loaded nanoparticle drug-gene therapy for metastatic breast cancer

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02396378	Topotecan Hydrochloride for Injection	Not listed	Not listed
02390981	Topotecan Injection	Not listed	Not listed
02379422	Topotecan Hydrochloride for Injection	Not listed	Not listed
02441071	Teva-Topotecan	Not listed	Not listed

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (topoisomerase I inhibitor, camptothecin class)
Myelosuppression Risk	High (neutropenia, thrombocytopenia and anaemia are consistent with the contraindication-related conditions listed in the knowledge graph)
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Complete blood count with differential, liver and renal function
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

Contraindication-related conditions (from the knowledge graph, not label text): thrombocytopenia, neutropenia, agranulocytosis, anaemia, macrocytic anaemia, interstitial lung disease, diarrhoeal disease, impaired renal function, pulmonary fibrosis, postinflammatory pulmonary fibrosis.
Drug interactions: 100 interactions were recorded. The more significant ones include:
- Major: deferiprone, samarium (153Sm) lexidronam
- Moderate: eliglustat, rolapitant, iobenguane (I-131), palifermin, strontium chloride Sr-89, ibritumomab tiuxetan
- Minor: levofloxacin, caffeine

Official package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for complete safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is very high, but the supporting clinical evidence for breast cancer is weak: the only breast-specific Phase 2 study was terminated, one infusional Phase 2 study showed no increased efficacy, and the rest is preclinical, review or indirect material. Package insert safety data are also missing, so safety screening cannot proceed yet.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (currently a blocking gap)
Mechanism of action data from DrugBank
Clinical data specific to topotecan in breast cancer, particularly triple-negative or MYC-driven subtypes
A review of the myelosuppression, pulmonary and renal risks listed above before any further study
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.